FDA approves new indication for Novartis' Afinitor cancer drug
The US Food and Drug Administration (FDA) approved the use of Novartis' Afinitor (everolimus) to treat adult patients with neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin. Further global regulatory filings for the new indication are underway, with a decision in the European Union (EU) expected later this year.Afinitor is approved in 99 countries, including the US and throughout the EU, for locally advanced, metastatic or unresectable progressive NET of pancreatic origin.
Click on this link for more information.
